Abstract 2158P
Background
Screen failures (SF) in early phase clinical trial are deleterious for patients, physicians and drug companies. It is therefore crucial to identify risk factors of SF, in order to optimize drug development and maximize patient’s benefit.
Methods
We created a self-assessment survey (SCITEP score) comprising 15 questions extracted from the ESAS, EQ-5D and PALLIA 10 scores, which evaluate patient’s (pts) symptoms and quality of life, each item being scored from 0 to 10 (i.e total score between 0 and 150). Patients entering a phase I clinical trial (ph1T) at Gustave Roussy cancer center between January 10th and October 26th 2022 were evaluated at screening (T0), and subsequently every month (T1, T2,..) until end of treatment.
Results
227 of 275 pts entering a Ph1T were assessed between January 10th and October 26th 2022. Most frequent tumor types were lung (18%), GI (16%), hematological (10%) and gynecological cancer (9.3%); 56% were female. At data cut off (January 15th 2023), 25 pts were considered SF. There was no difference observed between SF pts and pts who went on with the trial in terms of ECOG, RMH score, albumin and LDH levels, number of previous lines of treatments and of metastatic sites at baseline (Table). At T0, there was a significant difference in the SCITEP score between SF pts and the others (median score 41 [IQR 26-63] vs 20 [IQR 10-38], p<0.001). Internal validity of the score was good (cronbach alpha > 0.7). With a cutoff of ≥35, sensitivity of the survey to identify pts at high risk of SF was of 66.6% and specificity of 70.5%. Regarding overall survival, pts with a score ≥35 (n= 68) at T0 were at higher risk of death (survival rate at 3 months of 53% vs 65%, p<0.01). Table: 2158P
SF pts (n= 25) | Non SF pts (n=202) | p-value | |
ECOG (IQR) | 1 (0-1) | 1 (0-1) | 0.3 |
RMH score (IQR) | 1 (0-1) | 1 (0-1) | 0.3 |
LDH level (IQR) | 260(185-433) | 222 (185-286) | 0.2 |
Albumin level (IQR) | 43 (36-45) | 43 (41-45) | 0.5 |
Nb of metastatic sites (IQR) | 2 (2-3) | 2 (2-3) | 0.4 |
Nb previous lines of treatment (IQR) | 3 (3-4) | 3 (2-4) | 0.04 |
SCITEP score (IQR) | 41 (26-63) | 20 (10-38) | <0.001 |
Conclusions
Self-assessment of risk of SF by pts entering a ph1T is feasible with the SCITEP score. A score ≥35 seemed associated with a higher risk of SF and of death at 3 months. Independent cohorts are needed to revalidate this score as a tool to better detect pts at risk of SF and thereby optimize drug development.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2204P - Clinical predictors and inflammatory markers for malignant pleural mesothelioma prognosis: A retrospective study in a Spanish Medical Oncology Unit
Presenter: Mora Guardamagna
Session: Poster session 07
2205P - Tumor-infiltrating lymphocytes score possesses a relation with adjuvant chemo-immunotherapy benefit and cellular morphology in large-cell neuroendocrine carcinoma
Presenter: Zhiwen Luo
Session: Poster session 07
2207P - Mainstream germline genetic testing in routine oncological care of EGFR mutant non-small cell lung cancer in the United Kingdom
Presenter: Hazel O'Sullivan
Session: Poster session 07
2208P - The single-cell proteomic landscape of pulmonary lymphoepithelioma-like carcinoma
Presenter: Chi Cho
Session: Poster session 07
2209P - Mutational status of non-small cell lung cancer in Portugal: A multicentric study
Presenter: Joana Duarte
Session: Poster session 07
2210P - Reprogramming of pyrimidine metabolism drives tumorigenesis in NF2-deficient malignant pleural mesothelioma
Presenter: Duo Xu
Session: Poster session 07
2234P - Local immune-related adverse events (irAEs) are more common in tumor-bearing organs
Presenter: Steve Blum
Session: Poster session 07
2235P - Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer
Presenter: Pietro Paolo Vitiello
Session: Poster session 07
2236P - MHC-II neoantigens and copy number alterations (CNA) drive immune checkpoint inhibitor (ICI) response in metastatic melanoma (MM)
Presenter: Benjamin Shum
Session: Poster session 07